Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
8(67%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_1
12
100%

Phase Distribution

12

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
12(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

8

trials recruiting

Total Trials

12

all time

Status Distribution
Active(8)
Completed(3)
Terminated(1)

Detailed Status

Recruiting7
Completed3
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
8
Success Rate
75.0%
Most Advanced
Phase 1

Trials by Phase

Phase 112 (100.0%)

Trials by Status

recruiting758%
active_not_recruiting18%
completed325%
terminated18%

Recent Activity

8 active trials
Showing 5 of 12
recruitingphase_1

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

NCT05929235
completedphase_1

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

NCT03978689
recruitingphase_1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

NCT05482893
completedphase_1

Study of DF9001 in Patients With Advanced Solid Tumors

NCT05597839
recruitingphase_1

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

NCT07158918
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05929235Phase 1

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Recruiting
NCT03978689Phase 1

A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Completed
NCT05482893Phase 1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Recruiting
NCT05597839Phase 1

Study of DF9001 in Patients With Advanced Solid Tumors

Completed
NCT07158918Phase 1

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

Recruiting
NCT05394103Phase 1

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
NCT05585034Phase 1

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Completed
NCT06963814Phase 1

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

Recruiting
NCT05205109Phase 1

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

Recruiting
NCT05970497Phase 1

A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors

Recruiting
NCT04130542Phase 1

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active Not Recruiting
NCT05996445Phase 1

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12